H Clifford Lane

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2159442/publications.pdf

Version: 2024-02-01

215 papers	41,881 citations	10351 72 h-index	2439 197 g-index
220 all docs	220 docs citations	220 times ranked	54805 citing authors

#	Article	IF	Citations
1	Remdesivir for the Treatment of Covid-19 â€" Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	13.9	5,834
2	DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology, 2003, 4, P3.	3.8	4,682
3	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807.	13.9	2,232
4	DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Research, 2007, 35, W169-W175.	6.5	1,934
5	DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021Âupdate). Nucleic Acids Research, 2022, 50, W216-W221.	6.5	1,694
6	Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1983, 309, 453-458.	13.9	1,653
7	DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology, 2003, 4, 1.	3.8	1,411
8	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Medicine, 2008, 5, e203.	3.9	1,398
9	Covid-19 â€" Navigating the Uncharted. New England Journal of Medicine, 2020, 382, 1268-1269.	13.9	1,393
10	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. New England Journal of Medicine, 2019, 381, 2293-2303.	13.9	1,171
11	DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics, 2012, 28, 1805-1806.	1.8	955
12	Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1985, 313, 79-84.	13.9	760
13	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. New England Journal of Medicine, 2021, 384, 619-629.	13.9	741
14	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. Journal of Clinical Oncology, 2015, 33, 74-82.	0.8	571
15	DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics, 2007, 8, 426.	1.2	510
16	HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Medicine, 1997, 3, 533-540.	15.2	501
17	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS ONE, 2012, 7, e44454.	1.1	456
18	Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection â€" A Preliminary Study. New England Journal of Medicine, 1995, 332, 567-575.	13.9	433

#	Article	IF	Citations
19	Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. New England Journal of Medicine, 1996, 335, 1350-1356.	13.9	429
20	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. New England Journal of Medicine, 2016, 375, 1448-1456.	13.9	429
21	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine, 1999, 5, 651-655.	15.2	400
22	Re-emergence of HIV after stopping therapy. Nature, 1999, 401, 874-875.	13.7	390
23	Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Medicine, 1995, 1, 330-336.	15.2	372
24	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	13.9	357
25	Diagnosis ofPneumocystis cariniiPneumonia: Improved Detection in Sputum with Use of Monoclonal Antibodies. New England Journal of Medicine, 1988, 318, 589-593.	13.9	352
26	Ophthalmic Involvement in Acquired Immunodeficiency Syndrome. Ophthalmology, 1984, 91, 1092-1099.	2.5	321
27	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. New England Journal of Medicine, 2017, 376, 330-341.	13.9	314
28	Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8783-8788.	3.3	282
29	ANTI-RETROVIRAL EFFECTS OF INTERFERON-Î± IN AIDS-ASSOCIATED KAPOSI'S SARCOMA. Lancet, The, 1988, 332, 1218-1222.	6.3	246
30	Trimetrexate for the Treatment ofPneumocystis cariniiPneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1987, 317, 978-985.	13.9	243
31	Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood, 2008, 112, 287-294.	0.6	243
32	Interferon-Î± in Patients with Asymptomatic Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 112, 805.	2.0	212
33	Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN. Journal of Immunology, 2011, 186, 4541-4545.	0.4	211
34	Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. Journal of Experimental Medicine, 2001, 194, 1731-1741.	4.2	203
35	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. New England Journal of Medicine, 2017, 377, 1438-1447.	13.9	199
36	EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO. Lancet, The, 1985, 326, 627-630.	6.3	190

#	Article	IF	Citations
37	Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunological Reviews, 1997, 160, 43-54.	2.8	187
38	Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1985, 78, 417-422.	0.6	180
39	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	0.6	165
40	Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2000, 284, 183.	3.8	158
41	Bioterrorism: A clear and present danger. Nature Medicine, 2001, 7, 1271-1273.	15.2	157
42	DAVID gene ID conversion tool. Bioinformation, 2008, 2, 428-430.	0.2	156
43	High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults. Annals of Internal Medicine, 2002, 137, 17.	2.0	153
44	Defective HIV-1 proviruses produce viral proteins. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3704-3710.	3.3	150
45	A Randomized Trial of Highâ€•versus Lowâ€Ðose Subcutaneous Interleukinâ€2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1999, 179, 849-858.	1.9	149
46	HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet, The, 1999, 353, 119-120.	6.3	142
47	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 36-43.	0.9	142
48	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 622-635.	4.6	135
49	Clinical Pharmacokinetics of Suramin in Patients With HTLVâ€III/LAV Infection. Journal of Clinical Pharmacology, 1986, 26, 22-26.	1.0	130
50	Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins. Journal of Experimental Medicine, 1997, 185, 1381-1386.	4.2	126
51	Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nature Medicine, 1998, 4, 852-856.	15.2	115
52	Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. Journal of Clinical Investigation, 2005, 115, 2139-2148.	3.9	115
53	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19851-19856.	3.3	111
54	Incomplete CD4 T Cell Recovery in HIV-1 Infection After 12 Months of Highly Active Antiretroviral Therapy Is Associated With Ongoing Increased CD4 T Cell Activation and Turnover. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 125-133.	0.9	110

#	Article	IF	Citations
55	CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. Clinical Infectious Diseases, 2004, 39, 115-122.	2.9	109
56	In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. Journal of Clinical Investigation, 2005, 115, 1839-1847.	3.9	109
57	Four Decades of HIV/AIDS â€" Much Accomplished, Much to Do. New England Journal of Medicine, 2020, 383, 1-4.	13.9	106
58	A Longitudinal Study of Ebola Sequelae in Liberia. New England Journal of Medicine, 2019, 380, 924-934.	13.9	104
59	Cutting Edge: L-Selectin (CD62L) Expression Distinguishes Small Resting Memory CD4+ T Cells That Preferentially Respond to Recall Antigen. Journal of Immunology, 2003, 170, 28-32.	0.4	101
60	STING is an essential mediator of the Ku70-mediated production of IFN-Î»1 in response to exogenous DNA. Science Signaling, 2017, 10, .	1.6	100
61	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 951-963.	5.2	99
62	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. Annals of Internal Medicine, 2022, 175, 969-979.	2.0	99
63	Noninfectious papilloma virusâ€"like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood, 2007, 109, 1841-1849.	0.6	94
64	IL-2â€"induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood, 2004, 104, 775-780.	0.6	93
65	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. PLoS ONE, 2012, 7, e24243.	1.1	89
66	IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. Aids, 2008, 22, 39-45.	1.0	86
67	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respiratory Medicine,the, 2017, 5, 500-511.	5.2	85
68	Zidovudine in Patients with Human Immunodeficiency Virus (HIV) Infection and Kaposi Sarcoma. Annals of Internal Medicine, 1989, 111, 41.	2.0	85
69	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood, 2011, 118, 6845-6848.	0.6	84
70	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 941-950.	5.2	83
71	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 325, 1534-1538.	13.9	82
72	The Evaluation of Subcutaneous ProleukinÂ® (interleukin-2) in a Randomized International Trial. Contemporary Clinical Trials, 2002, 23, 198-220.	2.0	81

#	Article	IF	Citations
73	Relative Replication Fitness of a High-Level 3â€²-Azido-3â€²-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrâ†'Gly) at Codon 69. Journal of Virology, 2000, 74, 10958-10964.	1.5	80
74	Peripheral t cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. American Journal of Medicine, 1987, 82, 539-545.	0.6	72
75	Inhibition of Immunoreactive Tumor Necrosis Factor-Â by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 1996, 174, 63-68.	1.9	71
76	Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infectious Diseases, The, 2017, 17, 1255-1265.	4.6	70
77	Effect of Aerosolized Pentamidine Prophylaxis on the Diagnosis ofPneumocystis cariniiPneumonia by Induced Sputum Examination in Patients Infected with the Human Immunodeficiency Virus. The American Review of Respiratory Disease, 1991, 144, 760-764.	2.9	69
78	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	0.6	69
79	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. Human Gene Therapy, 2005, 16, 1065-1074.	1.4	69
80	The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine and Growth Factor Reviews, 2012, 23, 207-214.	3.2	68
81	Partial Immune Reconstitution in a Patient with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1984, 311, 1099-1103.	13.9	67
82	IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. Journal of Experimental Medicine, 2013, 210, 517-534.	4.2	66
83	Combination chemotherapy of disseminated kaposi's sarcoma in patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1987, 82, 456-462.	0.6	65
84	Syngeneic Bone Marrow Transplantation and Adoptive Transfer of Peripheral Blood Lymphocytes Combined with Zidovudine in Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 113, 512.	2.0	65
85	Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10712-10717.	3.3	65
86	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 2017, 4, ofx262.	0.4	65
87	ILâ€15 acts as a potent inducer of CD4⁺CD25^{hi} cells expressing FOXP3. European Journal of Immunology, 2008, 38, 1621-1630.	1.6	64
88	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Annals of Internal Medicine, 2021, 174, 687-690.	2.0	64
89	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clinical Trials, 2016, 13, 49-56.	0.7	63
90	Human immunodeficiency virus disease: Changing patterns of intraocular inflammation. American Journal of Ophthalmology, 1998, 125, 374-382.	1.7	62

#	Article	IF	Citations
91	Host defense againstMycobacterium-avium complex. Journal of Clinical Immunology, 1988, 8, 234-243.	2.0	58
92	Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. Aids, 2014, 28, 1091-1099.	1.0	56
93	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	2.0	56
94	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. PLoS ONE, 2013, 8, e57121.	1.1	54
95	Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood, 2007, 110, 501-508.	0.6	51
96	CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. Aids, 2001, 15, 1765-1775.	1.0	50
97	Loss of NaiÌ^ve Cells Accompanies Memory CD4 + T-Cell Depletion during Long-Term Progression to AIDS in Simian Immunodeficiency Virus-Infected Macaques. Journal of Virology, 2007, 81, 893-902.	1.5	50
98	Research in the Context of a Pandemic. New England Journal of Medicine, 2021, 384, 755-757.	13.9	50
99	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	6.3	48
100	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood, 2004, 103, 3282-3286.	0.6	47
101	Activated plateletâ€"T-cell conjugates in peripheral blood of patients with HIV infection. Aids, 2015, 29, 1297-1308.	1.0	45
102	Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. Biochemical and Biophysical Research Communications, 2013, 434, 228-234.	1.0	43
103	Immunologic Reconstitution in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1985, 103, 714.	2.0	42
104	Atovaquone Suspension in HIV-Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP-SMX Interaction Study. Pharmacotherapy, 1999, 19, 1050-1056.	1.2	41
105	Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood, 2011, 118, 262-270.	0.6	40
106	An open-label phase 1 clinical trial of the anti-Î± ₄ Î² ₇ monoclonal antibody vedolizumab in HIV-infected individuals. Science Translational Medicine, 2019, 11, .	5.8	40
107	Laboratory Methods in the Diagnosis and Prognostic Staging of infection with Human Immunodificiency Virus Type 1. Clinical Infectious Diseases, 1990, 12, 912-930.	2.9	39
108	Immune reconstitution in HIV infection. Current Opinion in Immunology, 1997, 9, 568-572.	2.4	39

#	Article	IF	Citations
109	High-Level Resistance to 3â€²-Azido-3â€²-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 1023-1028.	1.5	38
110	Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. Aids, 2000, 14, 1709-1715.	1.0	38
111	Enhanced Effector Function of CD8+ T Cells From Healthy Controls and HIV-Infected Patients Occurs Through Thrombin Activation of Protease-Activated Receptor 1. Journal of Infectious Diseases, 2013, 207, 638-650.	1.9	38
112	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. PLoS ONE, 2016, 11, e0167091.	1.1	38
113	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Annals of Internal Medicine, 2021, 174, 93-95.	2.0	38
114	A phase I trial of recombinant human interferon-Î³ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). Journal of Clinical Immunology, 1989, 9, 351-361.	2.0	37
115	Macrophage-Tropic Simian/Human Immunodeficiency VirusChimeras Use CXCR4, Not CCR5, for Infections of Rhesus MacaquePeripheral Blood Mononuclear Cells and AlveolarMacrophages. Journal of Virology, 2003, 77, 13042-13052.	1.5	37
116	Interferon-Î± Produces Significant Decreases in HIV Load. Journal of Interferon and Cytokine Research, 2010, 30, 461-464.	0.5	37
117	Comparison of the Quantiplex Version 3.0 Assay and a Sensitized Amplicor Monitor Assay for Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Samples. Journal of Clinical Microbiology, 1999, 37, 3612-3614.	1.8	37
118	Conducting clinical trials in outbreak settings: Points to consider. Clinical Trials, 2016, 13, 92-95.	0.7	35
119	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of â‰¥300/mm3: CPCRA 059. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 221-231.	0.9	34
120	A Phase I Study of Interferon-Î±2b in Combination with Interleukin-2 in Patients with Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1994, 169, 981-989.	1.9	33
121	A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. Aids, 2000, 14, 2509-2513.	1.0	33
122	Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles. Journal of Virology, 2001, 75, 3988-3992.	1.5	32
123	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of â‰¥300/mm3: CPCRA 059. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 221-231.	0.9	32
124	Effects of Intermittent Interleukinâ€2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasiâ€Species Expression. Journal of Infectious Diseases, 2000, 182, 1063-1069.	1.9	31
125	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. PLoS ONE, 2014, 9, e101785.	1.1	31
126	Kaposi's Sarcoma of the Head and Neck in the Acquired Immune Deficiency Syndrome. Otolaryngology - Head and Neck Surgery, 1984, 92, 255-260.	1.1	30

#	Article	IF	Citations
127	The CD8⁺HLAâ€DR⁺ T cells expanded in HIVâ€1 infection are qualitatively identical to those from healthy controls. European Journal of Immunology, 2012, 42, 2608-2620.	1.6	30
128	siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Research, 2014, 42, 583-598.	6.5	30
129	Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 2-6.	2.9	30
130	A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical Twins. Human Gene Therapy, 1993, 4, 659-680.	1.4	29
131	Evaluation of an antibody to Î± ₄ Î² ₇ in the control of SIVmac239- nef-stop infection. Science, 2019, 365, 1025-1029.	6.0	29
132	Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. Cytokine and Growth Factor Reviews, 2013, 24, 571-577.	3.2	28
133	Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness. Journal of Virology, 2006, 80, 6136-6145.	1.5	26
134	Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients. Aids, 2016, 30, 2487-2493.	1.0	26
135	Decreased CD127 Expression on T Cells in HIV-1-infected Adults Receiving Antiretroviral Therapy With or Without Intermittent IL-2 Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 537-544.	0.9	24
136	Chronic Exposure to Type-I IFN under Lymphopenic Conditions Alters CD4 T Cell Homeostasis. PLoS Pathogens, 2014, 10, e1003976.	2.1	24
137	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. Clinical Infectious Diseases, 2021, 73, 1849-1856.	2.9	24
138	Longitudinal Changes in CD4+T Cell Antigen Receptor Diversity and Naive/Memory Cell Phenotype during 9 to 26 Months of Antiretroviral Therapy of HIV-Infected Patients. AIDS Research and Human Retroviruses, 2000, 16, 1877-1886.	0.5	23
139	Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13813-13818.	3.3	22
140	INSIGHT FLU005: An Antiâ€“Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. Journal of Infectious Diseases, 2016, 213, 574-578.	1.9	22
141	A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100â€“300 CD4+ t cells. Clinical Immunology, 2003, 106, 188-196.	1.4	21
142	Regulatory T Cells in HIV-1 Infection: The Good, the Bad, and the Ugly. Journal of Infectious Diseases, 2012, 205, 1479-1482.	1.9	21
143	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Science Translational Medicine, 2019, 11, .	5.8	21
144	Increasing CD4+T Cells Specific for Tuberculosis Correlate with Improved Clinical Immunity after Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2002, 18, 969-975.	0.5	20

#	Article	IF	Citations
145	Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression. Journal of Virology, 2003, 77, 1011-1020.	1.5	20
146	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience. AIDS Patient Care and STDs, 2011, 25, 29-36.	1.1	20
147	Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. Scientific Reports, 2017, 7, 43441.	1.6	20
148	An observational prospective cohort study of the epidemiology of hospitalized patients with acute febrile illness in Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0007927.	1.3	20
149	Immunologic Abnormalities in HIV Infection. Hematology/Oncology Clinics of North America, 1991, 5, 215-228.	0.9	19
150	A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UKâ€“Vanguard Study. PLOS Clinical Trials, 2006, 1, e3.	3.5	19
151	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood, 2002, 100, 2159-67.	0.6	19
152	Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss. JAMA - Journal of the American Medical Association, 2006, 296, 1523.	3.8	18
153	CD4 T Cell Survival after Intermittent Interleukinâ€2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIVâ€Infected Patients. Journal of Infectious Diseases, 2008, 198, 843-850.	1.9	18
154	Cerebrospinal Fluid HIV-1 Compartmentalization in a Patient With AIDS and Acute Varicella-Zoster Virus Meningomyeloradiculitis. Clinical Infectious Diseases, 2013, 57, e135-e142.	2.9	18
155	HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. Aids, 2013, 27, 1867-1877.	1.0	18
156	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapyâ€“Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. Journal of Infectious Diseases, 2019, 220, 1325-1334.	1.9	18
157	Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults. Aids, 2013, 27, 591-595.	1.0	17
158	RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. JCI Insight, 2022, 7, .	2.3	17
159	Effects of interferon-Î± in patients with aids-associated Kaposi's sarcoma are related to blood interferon levels and dose. Cytokine, 1990, 2, 247-252.	1.4	16
160	Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. Journal of Clinical Immunology, 1992, 12, 185-192.	2.0	16
161	Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. Journal of Clinical Immunology, 1993, 13, 185-192.	2.0	16
162	Immune-based therapies in HIV infection. Aids, 1996, 10, S159-164.	1.0	16

#	Article	IF	Citations
163	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of Internal Medicine, 2021, 174, 1151-1158.	2.0	16
164	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). Clinical Trials, 2022, 19, 52-61.	0.7	16
165	CD4+T Cell Responses to Interleukinâ€2 Administration in HIVâ€Infected Patients Are Directly Related to the Baseline Level of Immune Activation. Journal of Infectious Diseases, 2007, 196, 677-683.	1.9	15
166	IL-7â€“dependent STAT1 activation limits homeostatic CD4+ T cell expansion. JCI Insight, 2017, 2, .	2.3	15
167	Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 Infection. PLoS ONE, 2014, 9, e98989.	1.1	14
168	A Randomized, Doubleâ€Blinded, Placeboâ€Controlled Trial of Intermittent Administration of Interleukinâ€2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus. Journal of Infectious Diseases, 2003, 188, 531-536.	1.9	13
169	Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. Aids, 2006, 20, 361-369.	1.0	13
170	Interleukin-2 Inhibits HIV-1 Replication in Some Human T Cell Lymphotrophic Virus-1-infected Cell Lines via the Induction and Incorporation of APOBEC3G into the Virion. Journal of Biological Chemistry, 2013, 288, 17812-17822.	1.6	13
171	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110.	1.3	13
172	PREVAIL I Cluster Vaccination Study With rVSVÎ”G-ZEBOV-GP as Part of a Public Health Response in Liberia. Journal of Infectious Diseases, 2019, 219, 1634-1641.	1.9	12
173	Characterization of Ebola Virusâ€“Associated Eye Disease. JAMA Network Open, 2021, 4, e2032216.	2.8	12
174	Increases in CD4+ T Lymphocytes Occur Without Increases in Thymic Size in HIV-Infected Subjects Receiving Interleukin-2 Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 299-303.	0.9	10
175	BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. Clinical Immunology, 2004, 113, 248-255.	1.4	10
176	Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. Clinical Infectious Diseases, 2020, 70, 2317-2324.	2.9	10
177	A Transcription Inhibitor, Actinomycin D, Enhances HIV-1 Replication Through an Interleukin-6-Dependent Pathway. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 388-397.	0.9	9
178	Identification and Characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx Recombinant Subtypes in Mali, West Africa. AIDS Research and Human Retroviruses, 2009, 25, 45-55.	0.5	9
179	Biomarkers in HIV disease. Current Opinion in HIV and AIDS, 2010, 5, 459-462.	1.5	9
180	Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation. Journal of Neuroinflammation, 2018, 15, 207.	3.1	9

#	Article	IF	Citations
181	Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials, 2021, 22, 86.	0.7	9
182	The immunology of HIV infection. Journal of the American Academy of Dermatology, 1990, 22, 1202-1205.	0.6	8
183	A unique syndrome of immunodeficiency and autoimmunity associated with absent T cell CD2 expression. Journal of Clinical Immunology, 1994, 14, 359-367.	2.0	8
184	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	1.3	7
185	Natural Occurring Polymorphisms in HIV-1 Integrase and RNase H Regulate Viral Release and Autoprocessing. Journal of Virology, 2021, 95, e0132321.	1.5	7
186	Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study. Open Forum Infectious Diseases, 2022, 9, ofac052.	0.4	7
187	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. Aids, 2022, Publish Ahead of Print, .	1.0	7
188	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. Aids, 2021, 35, 193-204.	1.0	6
189	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. Journal of Infectious Diseases, 2021, 224, 2053-2063.	1.9	6
190	Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. Open Forum Infectious Diseases, 2021, 8, ofaa613.	0.4	6
191	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight, 2019, 4, .	2.3	6
192	Immunologic Approaches to the Therapy of HIV-1 Infection. Annals of the New York Academy of Sciences, 1993, 685, 687-696.	1.8	5
193	Cytokine-based therapies for HIV infection. Aids, 2001, 15, S183-S191.	1.0	5
194	HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	5
195	A Model of Federal Interagency Cooperation: The National Interagency Confederation for Biological Research. Biosecurity and Bioterrorism, 2014, 12, 144-150.	1.2	5
196	Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1â^'/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Infectious Diseases, 2020, 221, 523-533.	1.9	5
197	Acquired Immunodeficiency Syndrome. Dermatologic Clinics, 1990, 8, 771-786.	1.0	5
198	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Journal of Antimicrobial Chemotherapy, 2018, 73, 2186-2196.	1.3	4

#	Article	IF	Citations
199	Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. Southern African Journal of HIV Medicine, 2016, 17, 450.	0.3	4
200	Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. American Journal of Tropical Medicine and Hygiene, 2021, 105, 960-965.	0.6	3
201	QuasiSeq: profiling viral quasispecies via self-tuning spectral clustering with PacBio long sequencing reads. Bioinformatics, 2022, 38, 3192-3199.	1.8	3
202	CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. PLoS ONE, 2017, 12, e0187912.	1.1	2
203	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	0.6	2
204	Biologic Response Modifiers (Interleukins and Interferons). , 1996, , 493-511.		2
205	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. Aids, 2021, 35, 783-789.	1.0	2
206	Adult and paediatric haematology and clinical chemistry laboratory reference limits for Liberia. African Journal of Laboratory Medicine, 2020, 9, 1080.	0.2	2
207	Effects of Delays in Peripheral Blood Processing, Including Cryopreservation, on Detection of CD31 Expression on Naiˆve CD4 T Cells. Vaccine Journal, 2008, 15, 1141-1143.	3.2	1
208	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 207-215.	0.9	1
209	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1898-1906.	1.3	1
210	HIV antivirals and immune recovery. Nature Medicine, 1997, 3, 704-704.	15.2	0
211	Immune-based Therapies for HIV Infection. , 2004, , 931-945.		0
212	Infections in the immunocompromised host. , 2008, , 477-491.		0
213	The impact of the 2014 Ebola epidemic on HIV disease burden and outcomes in Liberia West Africa. PLoS ONE, 2021, 16, e0257049.	1.1	0
214	Tackling the burden of mumps in the military: A report of the Defense Health Board. Vaccine, 2021, 39, 6186-6188.	1.7	0
215	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. Human Gene Therapy, 2005, .	1.4	0